公开(公告)号：US12117446B2

公开(公告)日：2024-10-15

申请号：US17529700

申请日：2021-11-18

申请人： National Jewish Health

发明人： Donald Y. M. Leung ,  Elena Goleva ,  Lingbo Li

IPC分类号： G01N33/00 ,  C07K16/40 ,  C12N15/113 ,  C12Q1/48 ,  G01N33/573

CPC分类号： G01N33/573 ,  C07K16/40 ,  C12N15/1137 ,  C12Q1/485 ,  C07K2317/76 ,  C12N2310/14 ,  C12N2320/30 ,  G01N2333/91205 ,  G01N2333/91215 ,  G01N2800/122 ,  G01N2800/52 ,  G01N2800/7095

摘要： The present invention is directed toward novel methods to identify as well as to treat a subject having an inflammatory disease resistant to corticosteroids.

公开(公告)号：US12092648B2

公开(公告)日：2024-09-17

申请号：US17668261

申请日：2022-02-09

申请人： The Cleveland Clinic Foundation

发明人： Stanley L. Hazen ,  Zeneng Wang

IPC分类号： G01N33/53 ,  G01N33/68

CPC分类号： G01N33/6893 ,  G01N2800/122 ,  G01N2800/52

摘要： The present invention provides methods, kits, and compositions for: i) detecting the level of 3-bromotyrosine in a sample that has been treated to liberate 3-bromotyrosine from 4-O-glucuronide-3-bromotyrosine, and/or ii) detecting the level of 4-O-glucuronide-3-bromotyrosine, and/or the combined level of both 4-O-glucuronide-3-bromotyrosine and 3-bromotyrosine, in a sample that has not been treated to liberate 3-bromotyrosine from 4-O-glucuronide-3-bromotyrosine. In certain embodiments, such detected levels are used to: i) identify the presence, severity, or risk of an eosinophilic disorder (e.g., asthma or a TH2-high eosinophilic disorder); ii) identify therapy effective for treating asthma or an eosinophilic disorder; or iii) identify patients suitable for treatment with therapeutic agents targeted to asthma or an eosinophilic disorder.

公开(公告)号：US20240125800A1

公开(公告)日：2024-04-18

申请号：US18270194

申请日：2021-12-29

申请人： KANSAS STATE UNIVERSITY RESEARCH FOUNDATION ,  THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM

发明人： Stefan H. BOSSMANN ,  Obdulia COVARRUBIAS-ZAMBRANO ,  Sumia EHSAN ,  Kayla ESCHLIMAN ,  Massoud MOTAMEDI ,  Raul NERI ,  Jose COVARRUBIAS

IPC分类号： G01N33/68 ,  G01N33/542 ,  G01N33/543

CPC分类号： G01N33/6893 ,  G01N33/542 ,  G01N33/5434 ,  G01N2333/96425 ,  G01N2333/966 ,  G01N2800/122

摘要： Nanoparticle-based nanosensors comprising supramolecular recognition sequences, protease consensus sequences, post-translationally modifiable sequences, or sterically hindered benzylether bonds for specific interaction with a biological marker, and methods for rapid diagnosis of lung conditions using specified panels of target biomarkers.

公开(公告)号：US20180355033A1

公开(公告)日：2018-12-13

申请号：US15735558

申请日：2016-06-10

申请人： Dana-Farber Cancer Institute, Inc.

发明人： David K. Thomas ,  Todd R. Golub

IPC分类号： C07K16/28 ,  G01N33/50 ,  A61P43/00 ,  A61K31/4164

CPC分类号： C07K16/2803 ,  A61K31/00 ,  A61K31/4164 ,  A61K38/16 ,  A61P43/00 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/76 ,  G01N33/5023 ,  G01N2800/042 ,  G01N2800/10 ,  G01N2800/122 ,  G01N2800/32 ,  G01N2800/52

摘要： The invention provides therapeutic, engineered protein/peptide compositions comprising e.g., RAGE antibodies, T-cell receptors to target a RAGE receptor (including soluble forms thereof) directly and/or via differential competition with one or more pre-cachexia and/or cachexia-associated RAGE ligands or markers.

公开(公告)号：US09945872B2

公开(公告)日：2018-04-17

申请号：US13541462

申请日：2012-07-03

申请人： Jason Flora ,  Barbara K. Zedler ,  Edward Lenn Murrelle ,  Mark Leppert ,  Edwin J. C. G. van den Oord ,  Bradley Todd Webb ,  Timothy York ,  Gaurav S. J. B. Rana ,  Jeffrey S. Edmiston ,  Willie J. McKinney

发明人： Jason Flora ,  Barbara K. Zedler ,  Edward Lenn Murrelle ,  Mark Leppert ,  Edwin J. C. G. van den Oord ,  Bradley Todd Webb ,  Timothy York ,  Gaurav S. J. B. Rana ,  Jeffrey S. Edmiston ,  Willie J. McKinney

IPC分类号： G01N33/68 ,  C40B40/10 ,  C07K17/00 ,  C07H21/00 ,  C40B40/08 ,  C40B20/02 ,  G01N33/574

CPC分类号： G01N33/6893 ,  C07H21/00 ,  C07K17/00 ,  C40B20/02 ,  C40B40/08 ,  C40B40/10 ,  G01N33/57423 ,  G01N33/6848 ,  G01N2800/12 ,  G01N2800/122 ,  G01N2800/60

摘要： Cigarette smoking is a primary determinant of chronic obstructive pulmonary disease (COPD), which is the fourth leading cause of morbidity and mortality in the United States. Unique proteins associated with COPD capable of differentiating subjects likely to experience rapid (RPD) or slow (SLW) decline in lung function have been identified using comprehensive high-throughput proteomic approaches. Thirty peptides, which mapped to 21 unique proteins, were linearly associated with annualized rates of lung function decline among smokers with COPD characterized as having rapid or slow decline and smokers without COPD. Using three different statistical approaches to assess the data, the RPD and SLW groups are differentiated by 55 peptides, which mapped to 33 unique proteins. A number of the identified peptides are proteolytic fragments of proteins that are involved in the complement and/or coagulation systems, have anti-protease activity, or metabolic functions.

公开(公告)号：US09885085B2

公开(公告)日：2018-02-06

申请号：US11770074

申请日：2007-06-28

申请人： John Hoidal ,  Mary Beth Scholand ,  Mark F. Leppert ,  Michael S. Paul ,  Robert Mark Gritz ,  Joel Gardner Pounds ,  Richard Dale Smith

发明人： John Hoidal ,  Mary Beth Scholand ,  Mark F. Leppert ,  Michael S. Paul ,  Robert Mark Gritz ,  Joel Gardner Pounds ,  Richard Dale Smith

IPC分类号： C12Q1/68 ,  G01N33/68 ,  G06F19/18

CPC分类号： C12Q1/6883 ,  G01N33/6848 ,  G01N2800/122 ,  G06F19/18

摘要： Methods are disclosed for generating and isolating an informative content repository of respiratory related biomarkers to accurately determine whether an individual has normal or abnormal pulmonary function. Specifically, methods are directed to determination of whether individuals have chronic obstructive pulmonary disease, and if so, whether the affected individuals experience rapid long decline or slow lung decline as a result of COPD. Also disclosed is an informative content repository of chronic obstructive pulmonary disease biomarkers, which when linked with other informative content provides a powerful tool for diagnosis, study, therapeutic discovery and development, condition management, health maintenance, and linking chronic obstructive pulmonary disease through pattern of life style, environmental exposure, and genetic susceptibility and inheritance. Disclosed herein is a chronic obstructive pulmonary disease biomarker informative content repository comprising at least one COPD biomarker, apparatus and methods to diagnose, assess, address, and ameliorate related conditions.

公开(公告)号：US20180016343A1

公开(公告)日：2018-01-18

申请号：US15627669

申请日：2017-06-20

申请人： Sanofi Biotechnology ,  Regeneron Pharmaceuticals, Inc.

发明人： Marius Ardeleanu ,  Namita A. Gandhi ,  Neil Graham ,  Stephane C. Kirkesseli ,  Sudeep Kundu ,  Ross E. Rocklin ,  Allen Radin ,  Steven P. Weinstein ,  Jennifer Davidson Hamilton ,  Jeffrey Ming

IPC分类号： C07K16/28 ,  A61K39/395 ,  G01N33/68 ,  A61K45/06 ,  A61K39/00

CPC分类号： C07K16/2866 ,  A61K39/39541 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/54 ,  C07K16/247 ,  C07K2317/21 ,  C07K2317/565 ,  C07K2317/76 ,  C12Q1/6883 ,  C12Q2600/106 ,  C12Q2600/158 ,  G01N33/6854 ,  G01N33/6863 ,  G01N33/6893 ,  G01N2333/521 ,  G01N2800/122 ,  G01N2800/52

摘要： The present invention provides methods for treating or preventing asthma and associated conditions in a patient. The methods of the present invention comprise administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4R) antagonist, such as an anti-IL-4R antibody.

公开(公告)号：US20170275326A1

公开(公告)日：2017-09-28

申请号：US15611964

申请日：2017-06-02

申请人： GALECTO BIOTECH AB

发明人： Neil Henderson ,  Tariq Sethi ,  Alison Mackinnon ,  Hakon Leffler ,  Ulf Nilsson

IPC分类号： C07H19/056 ,  C07H3/04 ,  A61K9/00 ,  G01N33/68 ,  C07H5/10 ,  A61K31/7056 ,  A61K31/7016 ,  A61M15/00 ,  A61K31/7008

CPC分类号： C07H19/056 ,  A61K9/0075 ,  A61K9/0078 ,  A61K31/7008 ,  A61K31/7016 ,  A61K31/7056 ,  A61M15/00 ,  A61M15/0085 ,  A61M2202/064 ,  C07B2200/13 ,  C07H3/04 ,  C07H5/10 ,  G01N33/6893 ,  G01N2333/4724 ,  G01N2800/122

摘要： Provided is a compound of the general formula (I): The compound of formula (I) is suitable for treating pulmonary fibrosis, such as Idiopathic pulmonary fibrosis in a mammal. Also provided is a method for treatment of pulmonary fibrosis, such as Idiopathic pulmonary fibrosis in a human subject having a galectin-3 level indicative of pulmonary fibrosis or exacerbation of symptoms as well as a method for making said compound.

公开(公告)号：US20170189424A1

公开(公告)日：2017-07-06

申请号：US15313769

申请日：2015-05-27

申请人： GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED

发明人： Neil Christopher BARNES ,  Steven John PASCOE

IPC分类号： A61K31/58 ,  G01N33/50 ,  A61K31/138 ,  A61K31/439 ,  A61K9/00

CPC分类号： A61K31/58 ,  A61K9/0075 ,  A61K31/138 ,  A61K31/439 ,  G01N33/5091 ,  G01N2800/122 ,  G01N2800/52 ,  A61K2300/00

摘要： The present invention relates to pharmaceutical products comprising fluticasone furoate for use in the treatment of COPD patients, particularly a subgroup of COPD patients that through analysis have been identified as possessing an eosinophil blood count of≧150 cells/W. The present invention is further directed to methods for treating a patient with COPD which methods include identifying a patient that will respond to treatment and administering a pharmaceutical product of the present invention comprising fluticasone furoate to said patient.

公开(公告)号：US20170183402A1

公开(公告)日：2017-06-29

申请号：US15387324

申请日：2016-12-21

申请人： Mayo Foundation for Medical Education and Research

发明人： Young J. Juhn ,  Hirohito Kita ,  Melissa R. Snyder ,  Jenna Corrinne Podjasek ,  Chung II Wi ,  Euijung Ryu

IPC分类号： C07K16/24 ,  G01N33/68

CPC分类号： C07K16/241 ,  C07K16/244 ,  C07K16/247 ,  G01N33/6863 ,  G01N2333/54 ,  G01N2333/5406 ,  G01N2333/5409 ,  G01N2333/5437 ,  G01N2333/55 ,  G01N2333/57 ,  G01N2800/065 ,  G01N2800/102 ,  G01N2800/122

摘要： This document provided methods and materials involved in treating medical conditions. For example, methods and materials for using anti-Interleukin 4, anti-Interleukin 5, and/or anti-Interleukin 13 antibodies to treat asthma in a mammal identified as having a Th2 immune response using a whole blood cell-based cytokine whole blood cell-based cytokine assay are provided.